| Name | Title | Contact Details |
|---|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
StausOne Health Systems is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EnduraCare Therapy Management is the largest privately held provider of rehabilitation services.
Steininger Behavioral Care Services is a Cherry Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VetnCare is a collective of AAHA accredited animal hospitals located in Northern California that believe the highest standard of veterinary care comes from veterinarian owned hospitals, led by their clinical teams.